252 related articles for article (PubMed ID: 29533116)
1. The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature.
Balsa A; Lula S; Marshall L; Szczypa P; Aikman L
Expert Opin Biol Ther; 2018 May; 18(5):575-584. PubMed ID: 29533116
[TBL] [Abstract][Full Text] [Related]
2. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.
Ungprasert P; Thongprayoon C; Davis JM
Clin Rheumatol; 2016 Jul; 35(7):1795-803. PubMed ID: 26852316
[TBL] [Abstract][Full Text] [Related]
3. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.
Prado MS; Bendtzen K; Andrade LEC
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):985-995. PubMed ID: 28772079
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
Thibodaux RJ; Triche MW; Espinoza LR
Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
[TBL] [Abstract][Full Text] [Related]
5. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
Zisapel M; Zisman D; Madar-Balakirski N; Arad U; Padova H; Matz H; Maman-Sarvagyl H; Kaufman I; Paran D; Feld J; Litinsky I; Wigler I; Caspi D; Elkayam O
J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
8. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
[TBL] [Abstract][Full Text] [Related]
9. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis.
Salvarani C; Olivieri I; Pipitone N; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M;
Clin Exp Rheumatol; 2006; 24(1):70-8. PubMed ID: 16539822
[TBL] [Abstract][Full Text] [Related]
10. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
Ungprasert P; Thongprayoon C; Davis JM
Semin Arthritis Rheum; 2016 Feb; 45(4):428-38. PubMed ID: 26610638
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis.
Mok CC; Tsai WC; Chen DY; Wei JC
Expert Opin Biol Ther; 2016; 16(2):201-11. PubMed ID: 26560845
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?
De Simone C; Amerio P; Amoruso G; Bardazzi F; Campanati A; Conti A; Gisondi P; Gualdi G; Guarneri C; Leoni L; Loconsole F; Mazzotta A; Musumeci ML; Piaserico S; Potenza C; Prestinari F
Expert Opin Biol Ther; 2013 Dec; 13(12):1673-82. PubMed ID: 24107126
[TBL] [Abstract][Full Text] [Related]
13. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
[TBL] [Abstract][Full Text] [Related]
14. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
[TBL] [Abstract][Full Text] [Related]
15. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.
Maneiro JR; Salgado E; Gomez-Reino JJ
JAMA Intern Med; 2013 Aug; 173(15):1416-28. PubMed ID: 23797343
[TBL] [Abstract][Full Text] [Related]
17. Novel Treatment Concepts in Psoriatic Arthritis.
Boyd T; Kavanaugh A
Rheum Dis Clin North Am; 2015 Nov; 41(4):739-54. PubMed ID: 26476230
[TBL] [Abstract][Full Text] [Related]
18. Switching biologics in the treatment of psoriatic arthritis.
Merola JF; Lockshin B; Mody EA
Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive treatment of dactylitis in psoriatic arthritis.
Rose S; Toloza S; Bautista-Molano W; Helliwell PS;
J Rheumatol; 2014 Nov; 41(11):2295-300. PubMed ID: 25362714
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature.
Reddy SM; Crean S; Martin AL; Burns MD; Palmer JB
Clin Rheumatol; 2016 Dec; 35(12):2955-2966. PubMed ID: 27730309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
